Bright Uro, a medical device company with a mission to transform care for lower urinary tract symptoms (LUTS) through innovations in urodynamics, today announced the second closing of its Series A funding round, which was oversubscribed by nearly 40% above and secured a total of $32M for the company.
Laborie Medical Technologies (Laborie), a leading global provider of urology diagnostic and therapeutic solutions, remains the lead investor, and it is now joined by University of California (UC Investments), Freepoint Capital Group and Laurelin Investors. The additional funding will be used to support Bright Uro’s 2025 anticipated launch of its Glean™ Urodynamics System, as well as manufacturing capacity expansion and R&D activities to support expanding the future pipeline.
“The Glean system has the potential to significantly impact the urodynamics landscape, and we remain very supportive of the Bright Uro team,” said Michael Frazzette, President and CEO of Laborie. “This funding round will help enable improved patient and clinician access to the technology which directly aligns with Laborie’s mission of preserving and restoring human dignity.”
“The overwhelming interest from a diverse range of sophisticated investors is a true testament to the compelling mission we are on,” said Derek Herrera, founder and CEO of Bright Uro. “With this funding, we are well resourced for the launch of Glean in 2025, while also continuing to resource our pipeline of innovation. We have never been more confident in the expected impact Glean will have for clinicians and millions of patients suffering from urinary issues.”